Evidence map›Paper›PMID 37326348›Full record

ArticleCancer medicine2023

The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients.

Verónica Bolaños-Suárez, Ana Alfaro, Ana María Espinosa, Ingrid Medina-Martínez, Eligia Juárez, Nicolás Villegas-Sepúlveda, Marco Gudiño-Zayas, América Gutiérrez-Castro, Edgar Román-Bassaure, María Eugenia Salinas-Nieves and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Hexokinase 2 promotes tumor development and progression.American journal of cancer research · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Verónica Bolaños-SuárezUnidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-7639-6166
Ana AlfaroAnatomía Patológica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
Ana María EspinosaFarmacología Clínica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
Ingrid Medina-MartínezDepartamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Eligia JuárezUnidad de Medicina Genómica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
Nicolás Villegas-SepúlvedaDepartamento de Biomedicina Molecular, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.
Marco Gudiño-ZayasUnidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0003-3186-6854
América Gutiérrez-CastroUnidad de Medicina Genómica, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
Edgar Román-BassaureServicio de Oncología, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
María Eugenia Salinas-NievesServicio de Ginecología, Clínica de Colposcopia, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico.
Sergio Bruno-MuñozServicio de Ginecología, Clínica de Colposcopia, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico.
Carlos ArandaServicio de Oncología, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.
Oscar Flores-HerreraDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Jaime BerumenUnidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0001-6707-3317
Hospital General de México · MXUniversidad Nacional Autónoma de México · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with cervical cancer (CC) may experience local recurrence very often after treatment; when only clinical parameters are used, most cases are diagnosed in late stages, which decreases the chance of recovery. Molecular markers can improve the prediction of clinical outcome. Glycolysis is altered in 70% of CCs, so molecular markers of this pathway associated with the aggressiveness of CC can be identified.

methodsThe expression of 14 glycolytic genes was analyzed in 97 CC and 29 healthy cervical tissue (HCT) with microarray; only LDHA and PFKP were validated at the mRNA and protein levels in 36 of those CC samples and in 109 new CC samples, and 31 HCT samples by qRT-PCR, Western blotting, or immunohistochemistry. A replica analysis was performed on 295 CC from The Cancer Genome Atlas (TCGA) database.

resultsThe protein expression of LDHA and PFKP was associated with poor overall survival [OS: LDHA HR = 4.0 (95% CI = 1.4-11.1); p = 8.0 × 10

conclusionsLDHA and PFKP overexpression at the mRNA and protein levels was associated with poor OS and DFS and increased risk of death in CC patients regardless of FIGO stage. The measurement of these two markers could be very useful for evaluating clinical evolution and the risk of death from CC and could facilitate better treatment decision making.

Indexed as

PhosphofructokinasesUterine Cervical NeoplasmsBiomarkersFemaleGlycolysisHumansLactate Dehydrogenase 5L-Lactate DehydrogenaseRNA, MessengerBiomarkersLactate Dehydrogenase 5LDHA protein, humanL-Lactate DehydrogenasePhosphofructokinasesRNA, Messengercervical cancerglycolysislactate dehydrogenase A (LDHA)phosphofructokinase platelet (PFKP)risk of deathsurvival

Identifiers

PMID37326348
PMCPMC10417302
OpenAlexW4380872120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.